One problem: The Erbitux trial lacks a control group or a comparison to conventional chemotherapy, so the study does not show clear survival benefit.

FORBES: Puncturing The ImClone Hype

In conventional studies, patients are randomly assigned to a treatment or control group to reduce sources of bias.

WSJ: ALS Study Falls Short, But Use of Social Media Holds Promise